Haemonetics (HAE) Q1 FY27 earnings call

Haemonetics delivered a strong start to FY27, driven by broad-based execution across its core platforms, leading to profitable growth and robust cash generation. The company raised its full-year revenue and earnings guidance, reflecting first-quarter outperformance and confidence in its strategic investments, while maintaining a disciplined outlook for the remainder of the year. Strategic investments in portfolio enhancement and commercial execution are fueling durable growth.